Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Sunday share tips: Futura Medical, Serco

(Sharecast News) - The Sunday Times's Lucy Tobin told readers that shares of Futura Medical were worth a punt, even if there were no guarantees of a happy ending.

Although the company had just 14 staff and directors, it had a new product that worked, Eroxon, a gel for those suffering from erectile dysfunction, which did not require a prescription in order to be sold.

Given that the market for ED was expected to surpass $6bn in value by 2032, the business's future looked appealing.

And unlike rival products Viagra and Cialis, both of which required a prescription, Eroxon took just 10 minutes to work, not half an hour.

The company was expecting approval for Eroxon in Saudi Arabia in September and was working on having a US partner for commercialisation which would likely a surge in the share price.

"There are no guarantees of a happy ending, but it's a worthy punt. Buy."

The Financial Mail on Sunday's told readers to 'buy' shares of Serco, although it conceded that risks were not absent.

The outsourcer was well-placed to benefit form government outlays on immigration and defence in many regions of the world, the tipster argued.

On the flip-side, there were multiple potential risks.

For starters, making up the loss of Covid-related work "wasn't always easy".

Furthermore, the possibility existed that it might lose the Australian immigration contract that was up for renewal in 2023.

Serco also had a tendency to work in "high-profile" and "controversial" areas, including on immigration which in the past had led to scandal and had an extremely negative impact on its share prices.

"There's no suggestion that the current management is likely to lead the company into any problems like this though, since former chief executive Rupert Soames is credited with shaking out any problems at the business, leaving it in stronger shape.

"At 156p, the shares are a buy."

Share this article

Related Sharecast Articles

Sunday newspaper round-up: Middle East, Aston Martin, Defence
(Sharecast News) - Britons must accept that their country was now involved in the Middle East conflict, Tobias Ellwood said. The former defence minister warned that "nobody was in full control" of the growing conflict as more and more countries were sucked in. Ellwood also said that Tehran's strike had taken the conflict into a "new dangerous territory". - Sunday Telegraph
Friday newspaper round-up: Everton, AstraZeneca, Amazon
(Sharecast News) - Everton has paid about £30m in interest charges to an opaque lender associated with a tax exile, corporate records suggest. The charges appear to have reached about £438,000 a week, according to the troubled Premier League club's most recent set of accounts, a figure more than three times the reported wages of the Everton and England goalkeeper Jordan Pickford. - Guardian
Thursday newspaper round-up: Border controls, McKinsey, KPMG
(Sharecast News) - New post-Brexit UK border controls coming into force later this month will cost British businesses £2bn and fuel higher inflation, according to a report warning that UK-EU trade will be damaged as a result. With less than a month before the introduction of new checks on animal and plant products from 30 April, the insurer Allianz Trade said the controls agreed under Boris Johnson's Brexit deal could add 10% to import costs over the first year. - Guardian
Wednesday newspaper round-up: Shoplifting, EnQuest, Klarna
(Sharecast News) - The government is investing more than £55m in expanding facial recognition systems - including vans that will scan crowded high streets - as part of a renewed crackdown on shoplifting. The scheme was announced alongside plans for tougher punishments for serial or abusive shoplifters in England and Wales, including being forced to wear a tag to ensure they do not revisit the scene of their crime, under a new standalone criminal offence of assaulting a retail worker. - Guardian

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.